284 related articles for article (PubMed ID: 15984537)
21. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia.
Fujiwara H; Arima N; Ohtsubo H; Matsumoto T; Kukita T; Kawada H; Imaizumi R; Ozaki A; Matsushita K; Tei C
Am J Hematol; 2002 Oct; 71(2):80-4. PubMed ID: 12353304
[TBL] [Abstract][Full Text] [Related]
22. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
[TBL] [Abstract][Full Text] [Related]
23. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
24. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index.
Møller MB; Pedersen NT; Christensen BE
Br J Haematol; 2006 Apr; 133(1):43-9. PubMed ID: 16512827
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
26. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
[TBL] [Abstract][Full Text] [Related]
27. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
[TBL] [Abstract][Full Text] [Related]
28. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
[TBL] [Abstract][Full Text] [Related]
29. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
30. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma.
Pérez-Encinas M; Villamayor M; Campos A; González S; Bello JL
Haematologica; 1998 Aug; 83(8):752-4. PubMed ID: 9793264
[TBL] [Abstract][Full Text] [Related]
31. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
Klapper W; Hoster E; Rölver L; Schrader C; Janssen D; Tiemann M; Bernd HW; Determann O; Hansmann ML; Möller P; Feller A; Stein H; Wacker HH; Dreyling M; Unterhalt M; Hiddemann W; Ott G;
J Clin Oncol; 2007 Aug; 25(22):3330-6. PubMed ID: 17664481
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic factors and predictive model of non-Hodgkin's lymphoma: pathological prognostic groupings and international prognostic index].
Shimoyama M
Nihon Rinsho; 2000 Mar; 58(3):602-11. PubMed ID: 10741132
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
Tsartsidze E; Betaneli M
Georgian Med News; 2006 May; (134):107-9. PubMed ID: 16783081
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
35. The usefulness of cell surface markers in predicting the prognosis of non-Hodgkin's lymphomas.
Baird S
Crit Rev Clin Lab Sci; 1993; 30(1):1-28. PubMed ID: 8489735
[TBL] [Abstract][Full Text] [Related]
36. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic and prognostic value of the immunohistochemical study of proliferating cell nuclear antigen (PCNA) expression in paraffin sections from non-hodgkin's lymphoma].
Gómez Arbonés X; Campo Güerri E; Virgili JM; Panades Siurana MJ
Sangre (Barc); 1995 Dec; 40(6):520-1. PubMed ID: 8850240
[No Abstract] [Full Text] [Related]
38. Reliability of histopathologic diagnosis of malignant lymphoma.
Hakama M; Franssila K; Saxén E
Ann Clin Res; 1973 Apr; 5(2):104-8. PubMed ID: 4584011
[No Abstract] [Full Text] [Related]
39. [A new system of diagnosis and classification--malignant lymphoma].
Shirakawa S; Kita K; Ohno T; Miwa H
Nihon Rinsho; 1992 Jun; 50(6):1200-8. PubMed ID: 1518135
[TBL] [Abstract][Full Text] [Related]
40. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
